KR20120008029A - 면역 조절 치료제 - Google Patents

면역 조절 치료제 Download PDF

Info

Publication number
KR20120008029A
KR20120008029A KR1020117023511A KR20117023511A KR20120008029A KR 20120008029 A KR20120008029 A KR 20120008029A KR 1020117023511 A KR1020117023511 A KR 1020117023511A KR 20117023511 A KR20117023511 A KR 20117023511A KR 20120008029 A KR20120008029 A KR 20120008029A
Authority
KR
South Korea
Prior art keywords
fibrinopeptide
activity
formulation
patient
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117023511A
Other languages
English (en)
Korean (ko)
Inventor
미첼 제이. 멜링
웨이드 엠. 멜링
Original Assignee
미첼 제이. 멜링
웨이드 엠. 멜링
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미첼 제이. 멜링, 웨이드 엠. 멜링 filed Critical 미첼 제이. 멜링
Publication of KR20120008029A publication Critical patent/KR20120008029A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
KR1020117023511A 2009-03-09 2010-03-09 면역 조절 치료제 Ceased KR20120008029A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15852609P 2009-03-09 2009-03-09
US61/158,526 2009-03-09

Publications (1)

Publication Number Publication Date
KR20120008029A true KR20120008029A (ko) 2012-01-25

Family

ID=42729052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117023511A Ceased KR20120008029A (ko) 2009-03-09 2010-03-09 면역 조절 치료제

Country Status (13)

Country Link
US (1) US20110318375A1 (https=)
EP (1) EP2405935A2 (https=)
JP (1) JP2012520306A (https=)
KR (1) KR20120008029A (https=)
CN (1) CN102439175A (https=)
AU (1) AU2010222851A1 (https=)
BR (1) BRPI1009569A2 (https=)
CA (1) CA2753871A1 (https=)
EC (1) ECSP11011373A (https=)
MX (1) MX2011009475A (https=)
RU (1) RU2011137856A (https=)
SG (1) SG174290A1 (https=)
WO (1) WO2010104854A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837358B (zh) 2012-12-14 2019-03-29 希尔氏宠物营养品公司 用于陪伴动物的抗衰老食物
EP3439683A4 (en) * 2016-04-04 2020-07-29 Marpe Holdings, LLC MODULATION OF THE IMMUNE SYSTEM FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS
JP2018163071A (ja) * 2017-03-27 2018-10-18 京都府公立大学法人 関節リウマチに関するペプチドマーカー
CN110045130B (zh) * 2019-04-17 2022-03-29 中山大学附属第一医院 一种与IgA肾病相关的多肽的免疫分析检测试剂盒
WO2025017038A2 (en) * 2023-07-17 2025-01-23 Angus Dalgleish Serum-derived peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673561B1 (en) * 1999-06-30 2004-01-06 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
WO2003065997A2 (en) * 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules
US20080294261A1 (en) * 2007-05-24 2008-11-27 Kevin Pauza Method for treating herniated discs

Also Published As

Publication number Publication date
RU2011137856A (ru) 2013-04-20
CA2753871A1 (en) 2010-09-16
ECSP11011373A (es) 2011-11-30
SG174290A1 (en) 2011-10-28
WO2010104854A3 (en) 2010-11-04
BRPI1009569A2 (https=) 2016-03-22
AU2010222851A1 (en) 2011-09-15
US20110318375A1 (en) 2011-12-29
EP2405935A2 (en) 2012-01-18
CN102439175A (zh) 2012-05-02
JP2012520306A (ja) 2012-09-06
MX2011009475A (es) 2011-12-08
WO2010104854A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
JP2023105112A (ja) 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
EA007814B1 (ru) Пептиды, полученные из казеина, и их использование в терапии
KR20120008029A (ko) 면역 조절 치료제
CN1324244A (zh) 治疗脓毒症的方法
WO2021204170A1 (zh) 一种中华冀土鳖虫来源的具有降血脂功能的活性肽及其制备方法和应用
US20240239841A1 (en) Peptide and method for treating pain using the same
KR20110094343A (ko) 황기 추출물을 포함하는 조성물을 이용한 특발성 혈소판감소성자반병의 치료
CN103435692A (zh) 人参糖蛋白在治疗老年痴呆的药物和保健食品中的应用
RU2192882C1 (ru) Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
CA2577777A1 (en) Methods of healing wounds by administering human il-18
Ichiki et al. Cleavage of bacterial flagellin with proteolytic enzymes: II. Induction of enhanced delayed-type hypersensitivity to flagellin by peptic fragments of the protein
CA2284548A1 (en) The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf)
CN107083366A (zh) 表达水蛭素的过继免疫细胞及其制备方法和用途
UA78516C2 (en) Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
CN1536082A (zh) 水蛭素突变体的一种编码基因与高效表达菌株
JPH029600B2 (https=)
US20180264091A1 (en) Enzymatic fractions with anti-inflammatory activity
KR20100038968A (ko) 실크 펩타이드 및 사이토카인을 유효성분으로 함유하는 것을 특징으로 하는 면역 증강 또는 항암용 조성물
CN108484760A (zh) 一种抗蓖麻毒素免疫球蛋白F（ab’）2及其制备方法
CN1128810C (zh) 防治肝病的鲨鱼肝多肽结构及纯化
KR100538642B1 (ko) 목질진흙버섯으로부터 분리한 산성 프로테오-헤테로글리칸추출물을 함유하는 관절염 치료용 또는 예방용 조성물
KR20250035076A (ko) 비멘틴 항체의약품을 이용한 전신경화증 치료유효물질 조성물
JP2008094746A (ja) 炎症性疾患の治療又は予防剤
CN120966834A (zh) 一种靶向FcRn和FcγRs的双特异性纳米抗体及其制备方法和用途
JP5598504B2 (ja) 経口免疫寛容を誘導するペプチド組成物及びその製造方法

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20111006

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111006

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130527

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130812

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I